Hanmi Pharm’s ‘Olita’ accepted health insurance benefits even with liquid biopsy, soon to be decided

Published: 2018-01-31 11:50:44

Updated: 2018-01-31 11:50:44

The range of health insurance benefits for ‘Olita,’ a Hanmi Pharm’s 3^rd generation new drug for the treatment of non-small cell lung cancer, is expected to be extended to liquid biopsy patients.

According to the pharmaceutical industry on the 29^th, the Health Insurance Review & Assessment Service(HIRA) Cancer Committee reportedly passed an agenda to accept health insurance benefits for Olita i...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.